Diabetic Patients and Retinal Proliferation: An Evaluation of the Role of Vascular Endothelial Growth Factor (VEGF)

Abstract

Vascular endothelial growth factor (VEGF) has been shown to play a major role in intraocular neovascularisation in ischaemic retinal diseases. The aim of this study was to evaluate the concentration of VEGF in vitreous, aqueous and epiretinal membranes of diabetic and non-diabetic patients, with other pathological conditions requiring surgical intervention. Higher VEGF concentration were found in samples from the eyes of diabetic patients versus other pathologies as well as in epiretinal membranes versus the other eye compartments in diabetic patients. However, high VEGF levels were also found in retinal detachment and proliferative vitreoretinopathy of non-diabetic patients. We concluded that VEGF is produced locally and plays a fundamental, but not specific, role in diabetic retinal neovascularisation and proliferation.

Key words

VEGF - Diabetic retinopathy - retinal proliferation

References

• 1 Aiello L P, Avery R L, Arrigg P G, Keyt B A, Jampel H D, Shah S T, Pasquale L R, Thieme H, Iwamoto M A, Park J E. et al . Vascular endothelial growth factor in ocular fluid of patient with diabetic retinopathy and other retinal disorders.  New Engl J Med. 1994;  331 1480-1487
• 2 Aiello L P, Cahill M T, Wong J S. Systemic considerations in the management of diabetic retinopathy.  Am J Ophthalm. 2001;  132 760-776
• 3 Armstrong D, Augustin A J, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy, and macular pucker.  Ophtalmologica. 1998;  212 410-414
• 4 Borgstrom P, Bourdon M A, Hillan K J, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.  Prostate. 1998;  35 1-10
• 5 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
• 6 Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy.  Diabetes Metab Res Rev. 2000;  393-407
• 7 Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications.  Horm Res. 2000;  53 53-67
• 8 Clarkson J G, Green W R, Massof D. A histopathologic review of 168 cases of preretinal membrane.  Am J Ophthalmol. 1977;  84 1-17
• 9 Cross M J, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.  Trends Pharm Sci. 2001;  22 201-207
• 10 Cooper M E, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview.  Am J Hypertens. 2001;  14 475-486
• 11 Danis R, Massicotte S, Boldt C. Preretinal and optic nerve head neovascularization induced by photodynamic venous thrombosis in domestic pigs.  Arch Ophthalmol. 1993;  111 539-543
• 12 Ferrara N. Molecular and biological properties of vascular endothelial growth factor.  Metabolism. 1999;  48 1172-1178
• 13 Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E, Schatz H, Derwahl M. Increased levels of pletelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy.  Exp Clin Endocrinol Diabetes. 2000;  108 106-109
• 14 Gass J DR. In: Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment. St. Louis; CV Mosby Co 1977: 344
• 15 Gaudric A, N'Guyen T, Moenner M, Glacet-Bernard A, Barritault D. Quantification of angiogenesis due to fibroblast growth factor in a modified rabbit corneal model.  Ophthalmic Res. 1992;  24 181-188
• 16 Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D. Glypican‐1 is a VEGF₁₆₅ binding proteoglycan that acts as an extracellular chaperone for VEGF₁₆₅.  J Biol Chem. 1999;  274 10816-10822
• 17 Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as receptor for the 145-amino acid form of VEGF.  J Biol Chem. 2000;  275 18040-18045
• 18 Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes.  J Biol Chem. 2001;  276 18688-18694
• 19 Greene D A, Lattimer S A, Sima A A. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.  N Engl J Med. 1987;  316 599-606
• 20 Katsura Y, Okano T, Noritake M, Kosano H, Nishigori H, Kado S, Matsuoka T. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders.  Diabetes Care. 1998;  21 1759-1763
• 21 Kim J K, Li B, Winer J, Armanini M, Gillett N, Phillips H S, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo.  Nature. 1993;  362 841-844
• 22 Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis A P. Advanced glycation end products increase retinal vascular endothelial growth factor expression.  J Clin Invest. 1998;  101 1219-1224
• 23 Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy.  Arch Ophtalmol. 1994;  112 1476-1482
• 24 Nakagawa K, Chen Y X, Ishibashi H, Yonemitsu Y, Murata T, Hata Y, Nakashima Y, Sueshi K. Angiogenesis and its regulation: roles of vascular endothelial cell growth factor.  Semin Thromb Hemost. 2000;  26 61-66
• 25 Paques M, Massin P, Gaudric A. Growth factors and diabetic retinopathy.  Diabetes & Metabolism. 1997;  23 125-130
• 26 Joussen A M, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand S J, Rudge J, Yancopoulos G D, Adamis A P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.  Am J Pathol. 2002;  160 501-509
• 27 Hammes H P, Lin J, Bretzel R G, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.  Diabetes. 1998;  47 401-406
• 28 Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulates expression of vascular endothelial growth factor in proliferative diabetic retinopathy.  Br J Ophthalmol. 1996;  80 241-245
• 29 Pierce E A, Foley E D, Aiello L P, Smith L E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.  Proc Natl Acad Sci USA. 1995;  91 905-909
• 30 Risau W. Mechanisms of angiogenesis.  Nature. 1997;  386 671-674
• 31 Rivard A, Berthou-Soulie L, Principe N, Kearney M, Curry C, Branellec D, Semenza G L, Isner J M. Age dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity.  J Biol Chem. 2000;  275 29643-29647
• 32 Robbins S G, Mixon R N, Wilson D J. et al . Platelet derived growth factor ligands and receptors immunolocalized in proliferative retinal disease.  Invest Ophthalmol Vis Sci. 1994;  35 3649-3663
• 33 Shen B Q, Lee D Y, Gerber H P, Keyt B A, Ferrara N, Zioncheck T F. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro.  J Biol Chem. 1998;  273 29979-29985
• 34 Shepro D, Morel N M. Pericyte physiology.  FASEB J. 1993;  7 1031-1038
• 35 Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review.  Diabetologia. 2001;  44 129-146
• 36 Spranger J, Pfeiffer A F. New concepts in pathogenesis and treatment of diabetic retinopathy.  Exp Clin Endocrinol Diabetes. 2001;  109 (Suppl 2) S438-450
• 37 Wells J A, Murthy R, Chibber R, Nunn A, Molinatti P A, Kohner E M, Gregor Z J. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.  Br J Ophthalmol. 1996;  80 363-366
• 38 Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura and Yamamoto M H. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor.  J Biol Chem. 1997;  272 8723-8730